Fulvia Ceccarelli: Efficacy of Anifrolumab in Lupus-Associated Autoimmune Haemolytic Anaemia
Fulvia Ceccarelli, Associate Professor of Rheumatology at Sapienza University of Rome, shared a post on LinkedIn about a recent article she and her colleagues co-authores, published in Lupus Science and Medicine, adding:
“We are proud to share our last contribution on efficacy of anifrolumab on lupus autoimmune haemolytic anaemia.
The study is the result of a spontaneous and friendly collaboration among centers in various Italian region.”
Title: Targeting type I interferon in lupus autoimmune haemolytic anaemia: first report with anifrolumab
Authors: Fulvia Ceccarelli, Rossella De Angelis, Francesca Bottazzi, Danila Madonna, Melania Alessia Coscia, Noemi Italiano, Emanuela Praino, Emanuela Sabatini, Leonardo Santo, Lorenzo Cavagna, Fabrizio Conti
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM